Trial Profile
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults With Alcohol Use Disorder (AUD) and Selected Polymorphisms in the Serotonin Transporter and Receptor Genes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2024
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Alcoholism
- Focus Registrational; Therapeutic Use
- Acronyms ONWARD
- Sponsors ADial Pharmaceuticals
- 10 Apr 2024 Results published in the ADial Pharmaceuticals Media Release.
- 10 Apr 2024 According to an ADial Pharmaceuticals media release, data from this trial published in journal of Internal Medicine.
- 31 Oct 2023 According to an ADial Pharmaceuticals media release, the company will present the overview of trial results at The Annual International Society of Addiction Medicine Conference taking place November 2-4, 2023, in Marrakesh, Morocco.